If you have an FDA-cleared or CE-marked medical device and you are eyeing Latin America, this is the guide I wish someone had handed me 15 years ago. No fluff. No regulatory theory. Just what actually happens when you try to register a medical device in Latin America and how to not lose two years figuring it out.
The LATAM regulatory landscape: what sponsors get wrong from day one
Latin America is not one market. It is 20+ countries, each with its own regulatory authority, its own classification system, its own documentation requirements, and its own timeline that may or may not correlate with what is published on paper.
Sponsors from the US and Europe tend to make the same assumption: “We have FDA clearance, so the rest should be straightforward.” It is not. FDA clearance is a starting point, not a shortcut. Some countries recognize it. Some partially accept it. Others do not care at all and want a full dossier from scratch.
The region is also evolving fast. Brazil’s ANVISA introduced a regulatory reliance pathway in 2024 that leverages reviews from reference authorities like the FDA and EU notified bodies. Colombia modernized its device framework. Mexico is in the middle of a regulatory overhaul. If you are working off a playbook from 2019, it is already outdated.
That said, the opportunity is massive. Over 650 million people. Growing healthcare spend. Governments investing in hospital infrastructure. And far less competition than the US or EU because most medtech companies never figure out how to get in.
Key markets and their regulatory authorities
Here is a breakdown of the markets that matter most for medical device registration in LATAM, what each authority expects, and what you are actually dealing with on the ground.
Brazil: ANVISA
The largest market in the region and the most complex regulatory environment. ANVISA classifies devices into four risk classes (I, II, III, IV) and requires a Brazilian Registration Holder (BRH). You cannot register directly as a foreign manufacturer.
The big development: ANVISA’s IN 290/2024 introduced a reliance pathway that allows the agency to leverage prior assessments from recognized authorities (FDA, Health Canada, TGA, EU notified bodies). For Class III and IV devices with existing approvals, this can meaningfully reduce review times.
You will still need Portuguese translations of all technical documentation, a Brazilian GMP certificate (CBPF) for higher-risk devices, and patience. ANVISA is thorough. But the reliance pathway is a genuine step forward.
Mexico: COFEPRIS
Mexico uses a three-class system (I, II, III). COFEPRIS has historically been one of the slower agencies in the region, but recent reforms, including equivalence agreements and an updated regulatory framework, are changing the landscape.
For devices with FDA clearance, COFEPRIS offers an abbreviated pathway that can reduce documentation requirements. But “abbreviated” does not mean fast. Backlog is real. And you need an in-country legal representative and an import license (Licencia Sanitaria).
One thing sponsors underestimate: COFEPRIS may request additional clinical data or testing even for FDA-cleared devices. Do not assume your 510(k) summary is enough.
Colombia: INVIMA
Colombia classifies devices into four classes (I, IIa, IIb, III) following a system similar to the EU. INVIMA is actually one of the more predictable agencies when you know how to work with them.
They recognize FDA clearance and CE marking as supporting evidence, which can simplify the technical review. You need an in-country registration holder, Spanish translations, and a complete technical dossier. Class I devices go through a notification (not registration), which is faster.
INVIMA has been investing in digital platforms and streamlining processes. It is not the bottleneck it used to be.
Argentina: ANMAT
ANMAT uses a risk-based classification (I, II, III, IV) and requires a local authorized representative. Argentina can be unpredictable. Timelines shift depending on political and economic conditions, and documentation requirements are detailed.
All submissions must be in Spanish. ANMAT may request certificates of free sale (CFS) from the country of origin and may conduct its own technical assessment regardless of prior FDA or CE approval. Plan for longer timelines here.
Chile: ISP
Chile’s Instituto de Salud Publica classifies devices into four classes and has been modernizing its regulatory framework. ISP recognizes approvals from reference authorities, which can expedite review for devices already cleared by FDA or bearing CE marking.
The process is relatively straightforward compared to Brazil or Argentina. You need a local representative, Spanish documentation, and a certificate of free sale. Chile is often a good early-win market for sponsors building a LATAM portfolio.
Peru: DIGEMID
Peru’s DIGEMID oversees device registration with a classification system aligned to international standards. The agency accepts FDA and CE documentation as supporting evidence.
Timelines are moderate, but administrative requirements (notarized documents, legalized certificates, Spanish translations) can slow things down if you are not prepared. Having an experienced in-country partner is critical here.
Other markets worth noting
Ecuador (ARCSA), Panama (MINSA), Costa Rica, Uruguay, and the Dominican Republic all have their own registration requirements. None are as complex as Brazil, but each adds its own layer of documentation, translation, and local representation. The cumulative burden of registering across multiple smaller markets is where sponsors lose the most time and money.
Common pathways: FDA clearance and CE marking as your foundation
If you already have FDA 510(k) clearance, De Novo authorization, or PMA approval, you have a significant head start in most LATAM markets. Same goes for CE marking under the EU MDR.
Here is how it works in practice:
FDA clearance as predicate: Most LATAM agencies accept your FDA clearance letter, summary, and labeling as core evidence of safety and performance. Some (like ANVISA under the reliance pathway) will explicitly leverage the FDA’s technical review. Others use it as supporting documentation but still conduct their own assessment.
CE marking recognition: Countries with EU-aligned classification systems (Colombia, Chile, Ecuador) tend to accept CE marking documentation more readily. Your EU Declaration of Conformity, notified body certificate, and technical file become the backbone of your submission.
Certificate of free sale: Nearly every LATAM country requires a CFS from the country of origin, typically issued by the FDA (for US manufacturers) or the competent authority in the EU. This document proves the device is legally marketed in its home market.
The key insight: having FDA or CE approval does not eliminate the registration process. It shortens and simplifies it. You still need local representation, translated documents, country-specific forms, and in many cases, government fees paid upfront before review even begins.
Timeline expectations by country
This is the question every sponsor asks first. Here is an honest breakdown based on what we have seen across hundreds of registrations in the region:
Brazil (ANVISA): 6 to 18 months depending on device class and whether the reliance pathway applies. Class I/II notifications can be faster. Class III/IV with CBPF requirement runs longer.
Mexico (COFEPRIS): 6 to 12 months. The abbreviated pathway for FDA-cleared devices can shorten this, but backlog creates variance.
Colombia (INVIMA): 3 to 8 months. One of the more efficient agencies in the region, especially for devices with prior FDA or CE approval.
Argentina (ANMAT): 6 to 14 months. High variance depending on the political and economic environment.
Chile (ISP): 3 to 6 months. Consistently one of the faster markets.
Peru (DIGEMID): 4 to 10 months. Administrative requirements can add time if documentation is not perfectly prepared.
Smaller markets (Ecuador, Panama, Costa Rica, Uruguay, Dominican Republic): 2 to 6 months each, but the administrative burden per country adds up quickly when you are doing five or more simultaneously.
The pattern is clear: individual countries are manageable. The complexity is in doing many of them at the same time while keeping documentation, translations, and regulatory correspondence aligned across all of them.
The five mistakes that cost sponsors the most time
1. Letting the distributor hold the registration
This is the most common and most expensive mistake. A sponsor enters a LATAM market through a distributor, and the distributor registers the device in their own name. The sponsor now has market access, but they do not own the registration. If the relationship ends, the registration stays with the distributor. The sponsor has to start over.
Always register under your own name or through an independent registration holder you control.
2. Using a general translation vendor
Regulatory documents have a specific vocabulary that varies by regulator, by document type, and by therapeutic area. A term that ANVISA accepts in a clinical study report is not the same term INVIMA expects in the same section of the same document. General translation vendors produce grammatically correct documents that regulators reject on technical grounds. The rejection adds 4 to 8 weeks per cycle.
3. Treating each country as a standalone project
When you register in five countries sequentially, each one takes its full timeline. When you register in five countries simultaneously with a coordinated submission strategy, you compress the total timeline dramatically because regulatory reviews overlap.
4. Underestimating government fees
Every LATAM country charges registration fees, and they are not trivial. Brazil’s fees alone can run into the tens of thousands depending on device class. Argentina, Colombia, and Mexico all have their own fee schedules. Sponsors who budget only for consulting fees get surprised when government fees add 30 to 50 percent to the total cost.
5. Starting without a certificate of free sale
The CFS is required by almost every LATAM agency, and obtaining one from the FDA or an EU authority takes time. Sponsors who wait until the last minute to request it lose weeks or months before the submission can even begin.
The case for simultaneous multi-country registration
The sponsors who move fastest across Latin America are not the ones with the biggest regulatory teams. They are the ones who stopped trying to do it country by country.
Simultaneous registration across multiple markets works because:
The core dossier is the same. Your technical file, clinical data, and quality system documentation do not change between countries. What changes is the regulatory format, the language, the local forms, and the in-country representation.
Translations can be coordinated. A single translation effort that accounts for regulator-specific terminology across all target markets is faster and more accurate than translating separately for each country.
Regulatory reviews overlap. While ANVISA is reviewing your Brazilian submission, INVIMA is reviewing your Colombian one, and ISP is reviewing your Chilean one. The total elapsed time is closer to the longest single review than the sum of all reviews.
Government fees are predictable. When you know the full fee schedule upfront, there are no surprises midway through the program.
This is exactly what the bioaccess® LATAM Launch Subscription was built to do. One flat annual fee covers government fees, certified translations, in-country registration holders, regulatory liaison, and a Submission Guarantee across up to 19 LATAM markets. No per-country surprises. No sequential delays.
If you have an FDA-cleared or CE-marked device and want to understand what simultaneous registration across Latin America actually requires, start at bioaccessla.com/market-access.
Choosing the right regulatory partner
Not all regulatory partners in LATAM are created equal. Here is what to look for:
Multi-country operational presence. A partner with boots on the ground in multiple LATAM countries can coordinate simultaneous submissions. A partner who subcontracts country by country introduces communication layers and delays.
Regulatory translation capability. If your partner outsources translations to a general vendor, you will pay for it in rejection cycles. Look for partners with in-house regulatory linguists trained on the terminology of each target agency.
Track record with your device class. A partner who has registered Class III cardiovascular devices is not automatically the right choice for a Class I diagnostic. Regulatory complexity varies by therapeutic area, not just risk class.
Transparent fee structure. Government fees, translation costs, and in-country representation fees should all be quoted upfront. If your partner cannot give you a total program cost before you start, find one who can.
Registration ownership. Make sure the registration will be held in your name or by an independent holder you control. Never let a partner or distributor hold the registration in their name.
Getting started
The first step is not picking countries. The first step is getting your documentation ready: FDA clearance or CE certificate, certificate of free sale, technical file, quality system documentation, and labeling. Once those are in order, the country selection and submission strategy follow naturally based on your commercial priorities.
If you want to talk through what a multi-country registration program looks like for your specific device, reach out. This is what we do every day at bioaccess®.
Julio G. Martinez-Clark is CEO of bioaccess®, the first CRO dedicated to first-in-human clinical trials and medical device registration across Latin America. He writes about LATAM regulatory strategy at Med Device Online and hosts the Global Trial Accelerators™ podcast.
